Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say

10/20/2021 | 01:10am EST

NEW DELHI, Oct 19 (Reuters) - India has delayed committing supplies of vaccine to the COVAX global sharing effort, two sources told Reuters on Tuesday, a day after one of its key backers, the WHO, said the agency could not "cut corners" to approve a domestically developed vaccine.

The world's biggest vaccine maker resumed exports of COVID-19 doses this month for the first time since April. It has sent about 4 million https://www.reuters.com/world/india/india-resumes-vaccine-exports-domestic-stocks-build-up-officials-2021-10-13to countries such as neighbouring Bangladesh and Iran, but none to COVAX.

Delayed supplies to COVAX could disrupt inoculation drives in many African nations that rely on it for vaccines.

On Monday, in the run-up to an Oct. 26 meeting on Covaxin, India's first domestically developed COVID-19 vaccine, the World Health Organization (WHO) said it could not "cut corners https://www.reuters.com/business/healthcare-pharmaceuticals/who-expects-more-information-indias-bharat-biotech-its-covid-19-vaccine-2021-10-18 " in the approval decision.

One of the sources said it was "frustrating" that India had yet to confirm any supply to COVAX, despite a promise by the health minister last month to meet the commitment to COVAX and others during the quarter to December.

The sources, who have been briefed on the export talks, declined to be identified as they were not authorised to speak on the subject.

"We are still waiting for confirmation on when and how many doses we can expect when exports do resume, and are not aware of any specific delay," COVAX co-lead GAVI, the Global Alliance for Vaccines and Immunization, said in an email.

"Indian vaccines have a powerful role to play" in ending the pandemic, it added.

India's health ministry, WHO and the Serum Institute of India (SII), which is the world's biggest maker of vaccines, did not respond to requests for comment.

SII, contracted to supply hundreds of millions of doses of a version of the AstraZeneca vaccine to COVAX and countries such as Bangladesh, has more than tripled its output of the vaccine since April, to reach 220 million doses a month.

Indian government officials have said they are confident the WHO will soon approve emergency use of Covaxin, which accounts for 11% of the 990 million doses India has injected, with the rest mostly from AstraZeneca.

A few weeks ago, Adar Poonawalla, the chief executive of SII, told the Telegraph newspaper that the company would resume exports to COVAX in October.

"Initially these supplies will be small, but by January 2022, once we have satisfied domestic demands ... we will see large volumes go to COVAX," he added.

Before India halted overseas vaccine shipments in April to fill domestic demand, it donated or sold more than 66 million COVID-19 doses, including Covaxin.

(Reporting by Krishna N. Das; Additional reporting by Sanjeev Miglani; Editing by Clarence Fernandez)

ę Reuters 2021
All news about ASTRAZENECA PLC
02:19aAstraZeneca, Ionis to Co-Develop Protein Misfolding Disorder Drug
01:55aASTRAZENECA : Jefferies is now Neutral
12/06AstraZeneca, Pfizer-BioNTech's COVID-19 Jabs Work Well With Moderna Shot, UK Study Says
12/06Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response -UK stud..
12/06Odyssey buys drugmaker BenevolentAI in Europe's biggest SPAC deal
12/06Odyssey buys drugmaker BenevolentAI in Europe's biggest SPAC deal
12/06Odyssey Acquisition, BenevolentAI Sign Biggest European SPAC Merger Deal Worth $1.7 Bil..
12/06Novartis working on pan-coronavirus oral treatment, CEO says
12/06LONDON STOCK EXCHANGE : Reports of milder Omicron symptoms reassure investors
12/06Covid-19 Vaccination - Federal Govt Approves Booster Dose
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 926 M - -
Net income 2021 2 827 M - -
Net Debt 2021 25 337 M - -
P/E ratio 2021 36,6x
Yield 2021 2,54%
Capitalization 172 B 172 B -
EV / Sales 2021 5,49x
EV / Sales 2022 4,49x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 110,91 $
Average target price 137,71 $
Spread / Average Target 24,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC14.19%171 675
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091